Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Polycystic kidney disease

26.01.2006


NIH and PKD Foundation launch HALT-PKD treatment trials



The National Institutes of Health (NIH) and the PKD Foundation have launched two treatment trials for autosomal dominant polycystic kidney disease (ADPKD). The common inherited disorder is characterized by cysts in the kidneys and other organs, high blood pressure, and aneurysms (bulges in blood vessels, which may burst) in the brain. Symptoms usually appear between the ages of 30 and 40 and include back and side pain and headaches. About half of ADPKD patients eventually develop kidney failure and require dialysis or a kidney transplant. The first Halt Progression of Polycystic Kidney Disease (HALT-PKD) patient enrolled last week at Emory University in Atlanta, one of seven recruitment sites (www.pkd.wustl.edu/pkd-tn).

"Decades of clinical and basic studies by NIH and others have delivered this exciting opportunity for translational research," says Catherine M. Meyers, M.D., a kidney specialist who directs HALT-PKD at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Naturally, we appreciate the PKD Foundation’s invaluable guidance and support."


PKD Foundation President and CEO Dan Larson applauded the start of the trials. "PKD families are eager to learn of any potential benefits," says Larson. "Their hope and the hope of the PKD Foundation is that this will be a step toward finding a cure for PKD and improving the care and treatment of those it affects."

Carefully controlling blood pressure and using ACE-inhibitors or ARBs significantly delays or prevents kidney disease and failure from diabetes and other causes by reducing protein in the urine and preventing damage to the small blood vessels in the kidneys. Earlier trials of these treatments in PKD were not definitive, possibly because a small number of patients were involved.

Over the next 2 years, HALT-PKD will recruit more than 1,000 people with ADPKD and treat them for up to 4 years at centers in Atlanta, Boston, Cleveland, Denver, Kansas City, Kansas, and Rochester, Minnesota. The two trials will compare standard therapy using an angiotensin-converting enzyme inhibitor (ACE-inhibitor) to intensive therapy using both an ACE-inhibitor and an angiotensin receptor blocker (ARB). Patients will receive a device for measuring blood pressure at home, clinic visits, lab tests, and study medications at no charge. They will also have their kidney function estimated using a standard blood test measurement called eGFR and other measures to track progression of kidney disease.

HALT-PKD Study A, for people 15 to 49 years of age with early disease (eGFR >60), will also compare standard (120-130/70-80 mm Hg) and low (95-110/60-75 mm Hg) blood pressure targets and measure changes in cyst and kidney size using a Magnetic Resonance Imaging method developed by NIDDK’s Consortium for Radiologic Imaging Studies of PKD. Study B, for people 18 to 64 and more advanced disease (eGFR 30-60), will track the time it takes eGFR to drop by 50 percent, the need for kidney failure treatment, and patient deaths.

PKD affects an estimated 500,000 people, about 90 percent of whom have ADPKD. In 2003, 23,000 people with cystic kidney disease (mostly PKD) received dialysis or a kidney transplant, making it this country’s fourth leading cause of kidney failure. While genetic testing for ADPKD can help determine whether a family member can safely donate a kidney, testing can’t predict onset of symptoms or severity of the disease, which also increases the risk of heart attacks, strokes and early death compared to the general population.

Mary Harris | EurekAlert!
Further information:
http://www.nih.gov
http://www.pkd.wustl.edu/pkd-tn

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>